Morgan Lewis partner Kathy Sanzo spoke with Bloomberg Law about the efforts by drugmakers to produce a vaccine and navigate a web of US Food and Drug Administration (FDA) regulations. In the article, she discussed one of the biggest challenges with the FDA regulations for approving vaccine manufacturing facilities. “One of the issues for the U.S. industry is there’s just not a lot of those sites around,” said Kathy. “To the extent that we need additional capacity, you can’t just take a site that makes small molecule drugs and convert it into a biologic manufacturing site.”
Read the full Bloomberg Law article >>
Subscription may be required.